- Home
- RYOJ vs SER Comparison
RYOJ vs SER Comparison
Compare RYOJ & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RYOJ | SER |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.8M | 29.3M |
| IPO Year | 2025 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RYOJ | SER |
|---|---|---|
| Price | $2.60 | $1.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 22.2K | ★ 3.6M |
| Earning Date | 12-15-2025 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 115.48 | N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $11,523,472.00 | $116,000.00 |
| Revenue This Year | N/A | $134.46 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.85 | ★ N/A |
| Revenue Growth | ★ 12.88 | N/A |
| 52 Week Low | $1.81 | $1.71 |
| 52 Week High | $11.43 | $7.92 |
Technical Indicators
Market Signals| Indicator | RYOJ | SER |
|---|---|---|
| Relative Strength Index (RSI) | 36.37 | 31.98 |
| Support Level | $2.69 | $2.11 |
| Resistance Level | $3.23 | $3.14 |
| Average True Range (ATR) | 0.14 | 0.35 |
| MACD | -0.02 | -0.12 |
| Stochastic Oscillator | 0.00 | 2.03 |
Price Performance
Historical ComparisonAbout RYOJ rYojbaba Co. Ltd.
rYojbaba Co Ltd is engaged in improving and restoring physical and mental health diminished by work-related stress through consulting and health services. The company provides consulting services to labor unions and companies wishing to build constructive relationships with labor unions and health services to osteopathic clinics and osteopathic beauty salons to alleviate physical ailments created by work-related stress.
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.